For healthcare professionals only
GPnotebook

This promotional website has been developed, organised and funded by Boehringer Ingelheim.
The media partners for this activity are GPnotebook and Diabetes on the net. GPnotebook and Diabetes on the net have had no input into the content of this website.

Prescribing information for United Kingdom and the Republic of Ireland.
Adverse event reporting information can be found at the bottom of the page.

Webinar resources

Dr Sarah Jarvis, General Practitioner and Medical Broadcaster, London

Chair of the T2 Discussions webinar series alongside several experts

All onboard? A case-based approach to the practical management of type 2 diabetes during Ramadan and periods of fasting

Dr Sarah Jarvis and Alia Gilani

  • VIDEO
  • 38 min

Click here to view video

All onboard? A case-based approach to the practical management of type 2 diabetes during Ramadan and periods of fasting

  • Explore the principles of Ramadan and fasting, including why many people with a medical exemption may still choose to fast
  • Provide guidance on monitoring type 2 diabetes, adjusting medications and managing sick days during Ramadan
  • Apply strategies for managing type 2 diabetes during Ramadan to fictional case-based examples
  • VIDEO (SHORT)
  • 14 min

CLICK HERE TO VIEW SUMMARY VIDEO

  • DOWNLOADABLE DOCUMENT

Click here to download

All onboard? A case-based approach to managing type 2 diabetes in adults with complex comorbidities

Dr Sarah Jarvis and Professor Mike Cummings

  • VIDEO
  • 42 min

Click here to view video

All onboard? A case-based approach to managing type 2 diabetes in adults with complex comorbidities

  • Explore the burden of managing adults with type 2 diabetes and multiple/complex comorbidities
  • Understand how to overcome the challenges of joined-up care
  • Discuss the role of the diabetes multi-disciplinary team through case-based examples
  • VIDEO (SHORT)
  • 7 min

CLICK HERE TO VIEW SUMMARY VIDEO

  • DOWNLOADABLE DOCUMENT

Click here to download

All onboard? Addressing treatment non-adherence in the management of adults with type 2 diabetes

Dr Sarah Jarvis and Hannah Beba

  • VIDEO
  • 30 min

Click here to view video

All onboard? Addressing treatment non-adherence in the management of adults with type 2 diabetes

  • Understand the terminology and challenges of treatment non-adherence in adults with type 2 diabetes, and why early intervention matters
  • Explore how to address treatment non-adherence by considering the potential benefits of effective diabetes management
  • The importance of patient engagement, treatment optimisation and shared decision-making
  • VIDEO (SHORT)
  • 8 min

CLICK HERE TO VIEW SUMMARY VIDEO

  • DOWNLOADABLE DOCUMENT

Click here to download

  • Leaving soon

Chronic kidney disease in adult type 2 diabetes: Practical advice for screening, management and referral

Dr Sarah Jarvis and Dr Janaka Karalliedde

  • VIDEO
  • 41 min

Click here to view video

 Chronic kidney disease in adult type 2 diabetes: Practical advice for screening, management and referral

  • Define the importance and impact of chronic kidney disease in adults with type 2 diabetes and its association with cardiovascular disease
  • Examine best practice for managing chronic kidney disease in adults with type 2 diabetes including screening, coding, referrals, managing complications and treatment options
  • VIDEO (SHORT)
  • 10 min

CLICK HERE TO VIEW SUMMARY VIDEO

  • Patient leaflet

Click here to download

  • Webinar

Sarah Jarvis
Webinar Series Chair

Watch the most recent webinar

VIEW HERE
  • VIRTUAL WEBINARS

Initiated and funded by Boehringer Ingelheim

PC-GB-110175 | July 2024

Prescribing information for United Kingdom and the Republic of Ireland.

Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:
• monotherapy when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment
• in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control

The content has been reviewed and approved by the sponsoring company prior to its publication. Editorial support for this website has been provided by
OmniaMed Communications.

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard (UK) or https://www.hpra.ie/homepage/about-us/report-an-issue (IRE). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone) (UK) or 01 2913960 (IRE), Fax: +44 1344 742661, or by e-mail: [email protected].

PC-GB-110809 V4 | November 2025

PC-GB-109919 v8 | November 2025

Trajenta® (linagliptin) prescribing information: UK and ROI.

JARDIANCE® (empagliflozin) prescribing information: UK and ROI.

This website is for healthcare professionals in the United Kingdom and Republic of Ireland only.

To continue, please confirm that you are a healthcare professional in the United Kingdom or the Republic of Ireland by clicking below.

I am
I am not
Prescribing information for the United Kingdom and the Republic of Ireland 

You are leaving this site.

You are now leaving https://resources.gpnotebook.com/moving-forward-in-type-2-diabetes-management-with-glp-1ras-resource-hub/.
Links to external website are provided as a resource to the viewer.
This website is neither owned or controlled by Novo Nordisk.
Novo Nordisk accepts no responsibility for the content or services of the linked site.

OK
Cancel